Anecdotal evidence and pharmacoepidemiological studies in humans report reduced alcohol use by patients using GLP-1RAs for other indications
This matters especially for women dealing with cortisol-driven insulin resistance
Genes, sleep, stress, hormones, physical activity, and certain medications can impact weight management
[11] Clinical studies such as the SUSTAIN programme (semaglutide) and AWARD trials (dulaglutide) demonstrate that GLP-1 receptor agonists can reduce HbA1c by approximately 0.81.5% on average, with some patients achieving greater reductions depending on baseline values and adherence
Additionally, inhibition of CD38 in the AD mouse model restored NAD + levels, decreased mitochondrial ROS production and plaque depositions in the hippocampus and cortex, and improved cognitive abilities 158
Standard lab results at Stage 2 are almost always within normal range